AAFA develops policy statements, comments and letters of support regarding public policies that affect those with asthma and allergies. AAFA and other health-focused groups write these. We want our positions and statements to teach community and government leaders about related issues. We also support or oppose policies that affect those living with asthma and allergies.
Read our latest statements, comments and letters of support:
AAFA Testifies Before House Committee About H.R. 2468 – January 8, 2020
AAFA’s CEO and President, Kenneth Mendez participated in the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health hearing on Legislation to Improve Americans’ Health Care Coverage and Outcomes. Mendez provided his and AAFA’s support of H.R. 2468, the School-Based Allergies and Asthma Management Program Act. The bill is a bipartisan effort to promote health and safety for millions of children living with asthma and food allergies. The implementation of H.R. 2468 would promote and create a preference within the Centers for Disease Control and Prevention’s (CDC) existing asthma grant program for states that require schools to take a series of actions to address asthma and food allergies.
AAFA Sends Letter to FDA Requesting Sesame Labeling Discussion – December 18, 2019
AAFA and other organizations sent a letter to Anna Abram, the Deputy Commissioner for Policy, Legislation, and International Affairs of the Food and Drug Administration (FDA) requesting a meeting to discuss the status of the agency’s efforts in sesame labeling. The FDA has initiated action regarding sesame allergy, requesting information to inform potential labeling requirements. Uniform and easily understandable labels will help Americans with sesame allergies and their families safely navigate their food choices and avoid preventable reactions.
AAFA Signs Comment Letter on FDA's Proposed Rule on PMTAs – December 16, 2019
AAFA and other organizations submitted a comment letter on Docket No. 2019-N-2854, the proposed rule for Premarket Tobacco Product Applications and Recordkeeping Requirements. The proposed rule is designed to inform tobacco product manufacturers and the public about requirements for submission of Premarket Tobacco Product Applications (“PMTAs”), related recordkeeping requirements, requirements for post-market information gathering and reporting, and the process FDA will use in the evaluation of PMTAs. The comment letter addresses these areas with principal emphasis on the requirements for submission of PMTAs.
AAFA Signs Letter Urging Final Negotiations on FY 2020 Defense Appropriations Act –December 9, 2019
AAFA and 102 other organization sent a letter urging members of the U.S. House of Representatives and Senate to complete final negotiations on the fiscal year (FY) 2020 Defense Appropriations Act and move the bill through the House and Senate toward enactment. The organizations are concerned about the possibility of Congress enacting a long-term continuing resolution in lieu of a fiscal year 2020 Defense Appropriations Act. Per the Department of the Defense, under this scenario, the Congressionally Directed Medical Research Programs would receive no funding in fiscal year 2020. Failure to enact a final bill will have major negative health implications for the millions of Americans – especially veterans – suffering from chronic and debilitating disorders.
AAFA Sends Letter Supporting Dockets Relating to Epinephrine and Anaphylactic Policies –December 3, 2019
AAFA sent a letter to the Council of State Governments’ Suggested Legislation Committee leadership: Co-Chair Representative Kim Koppelman of the North Dakota House of Representatives, Co-Chair Representative Kevin Ryan of the Connecticut General Assembly; and Vice Chair Jerry L. Bassett of the Alabama Legislative Services Agency. The letter expresses AAFA’s strong support for Docket #07-41A-12, 2019 Illinois HB 3435; Docket #07-41A-13, 2019 New York SB 218; and Docket #07-41A-29, 2015 New Jersey A 304. These laws concern the regulation and coverage of epinephrine autoinjectors for children 18 and younger, anaphylactic policies for childcare services, and emergency administration of epinephrine to students for anaphylaxis, respectively. These pieces of legislation are evidence-based and will reduce reactions and risk for children and provide peace of mind to families managing food allergies if replicated in other states.
AAFA Signs Letter Supporting the 100% Clean Economy Act – November 21, 2019
AAFA and other health and medication organizations sent a letter to Representatives expressing support of the 100% Clean Economy Act and its goal of reaching net-zero climate pollution by 2050. Meeting this goal is essential to protecting public health. The groups support the Act’s requirement that federal agencies take actions that improve public health, especially among communities disproportionately impacted by air pollution and climate change. The nation must dramatically reduce greenhouse gas emissions while cleaning up other harmful emissions from polluting sources at the same time.
AAFA Signs Letter Urging Congress to Address Delayed Patient Access in Medicare Part D – November 18, 2019
AAFA and 22 other organizations sent a letter urging Congress to prioritize policies that support access to lower-cost generic drugs and biosimilars. The letter requests that any comprehensive drug pricing legislation addresses the pressing issue of delayed patient access to generic medicines in Medicare Part D. Failure to solve this problem will only increase beneficiary and health system costs, and harm patients who desperately need greater access to affordable medicines. Ensuring timely and proper access to affordable medicines is an important step in lowering patient costs at the pharmacy counter and reducing overall Medicare spending.
AAFA Releases Statement on Inhalers and Greenhouse Gases – November 14, 2019
AAFA released a statement regarding a recent study that found the delivery system used for some asthma medicines (gases used in metered dose inhalers) may have a negative impact on global warming. AAFA believes patients, healthcare providers, and policy makers must keep these findings in perspective. AAFA urges those with asthma to continue taking their asthma medicines as advised by their health care provider as asthma can be fatal without proper treatment. Different asthma medicines work well for different people and switching to a new medicine may be inappropriate. AAFA supports clean air policies and encourages people to take steps to reduce our individual contributions to climate change. However, we recommend focus remain on other large-scale improvements we can make to reduce carbon footprints, methane and ozone emissions.
AAFA Signs Letter Expressing Concern Over EPA Proposed Rule – November 13, 2019
AAFA and 61 other groups sent a letter to the House of Representatives expressing concern over the U.S. Environmental Protection Agency’s (EPA) “Strengthening Transparency in Regulatory Science” proposed rule. The group supports the goal of improving the transparency of science and access to data. However, there are many credible scientific studies where the exposure of raw data to the public is infeasible or would reveal confidential patient or research participant information. If EPA excludes studies because the data cannot be made public, people may be exposed to real harm. The result would be decisions affecting millions based on inadequate information that fails to include well-supported studies by expert scientists.
AAFA Signs Letter Thanking the House for H.R. 1922 Legislation – October 22, 2019
AAFA, as part of the Health Choices Coalition, sent a letter to the House of Representatives applauding efforts to restore over-the-counter (“OTC”) medications to full tax-preferred status, eliminating the need to first obtain a prescription. The House’s legislation, H.R. 1922, will create efficiencies and improve access to care within the U.S. healthcare system. Americans’ concerns about rising healthcare costs are growing. H.R. 1922 is a common-sense policy that will help American families better manage their healthcare needs. The Coalition also thanks the House for broadening support for this legislation by crafting a bipartisan bill that extends HSA/FSA eligibility to feminine hygiene products.
AAFA Signs Letter Thanking HHS for Leadership in Addressing E-Cigarette and Vaping Crisis – October 18, 2019
AAFA, as part of the Childhood Asthma Leadership Coalition (CALC), sent a letter to the Secretary of the U.S. Department of Health and Human Services (HHS) thanking the Secretary for his leadership in addressing the public health crisis created by e-cigarettes and vaping. We believe that HHS’s announcement that the Administration will remove all non-tobacco flavored e-cigarettes from the market is a step in the right direction towards ending the vaping epidemic and protecting children from exposure to these deadly toxins. CALC urges the Administration to move forward with urgency. Combating this epidemic immediately is essential to avoiding serious long-term and multi-generational health consequences.
AAFA Signs Letter with Feedback on ICER’s Proposed Updates to 2020 Value Assessment Framework – October 18, 2019
AAFA and other organizations sent a letter to Steven D. Pearson, MD, MSc, the president of the Institute for Clinical and Economic Review (ICER), regarding ICER’s proposed updates to its 2020 Value Assessment Framework. The letter urges ICER to put patients and people with disabilities at the center their assessments. ICER’s use of discriminatory methods in its value assessments gives insurers tools to restrict patient access, a tactic that puts the most vulnerable at an increased risk of worse health outcomes, increased out-of-pocket costs associated with their care, and potential adverse events. ICER’s value assessments do not promote affordability for patients, but instead give payers justification to create barriers to treatment coverage that benefit their own bottom line.
AAFA Signs Letter for Funding of National Asthma Control Program for FY 2020 –October 17, 2019
AAFA and other organizations sent a letter to House and Senate Subcommittees requesting that their versions of the Labor, Health and Human Services, Education and Related Agencies appropriations bill for Fiscal Year (FY) 2020 include the House’s position of $34 million for the Centers for Disease Control and Prevention’s (CDC) National Asthma Control Program (NACP). CDC recently announced that almost ten states, cities and other entities were approved for funding from the NACP but not funded for the next five-year cycle. The House’s appropriated amount of $34 million would ensure these states receive funding for the next cycle, to help combat the terrible human and economic burden caused by asthma.
AAFA Sends Comment Letter to ICER on 2020 Value Assessment Framework Proposed Updates – October 15, 2019
AAFA sent a comment letter to Steven D. Pearson, MD, MSc, the president of the Institute for Clinical and Economic Review (ICER), regarding ICER’s proposed updates to its 2020 Value Assessment Framework. ICER has an opportunity to expand its inclusion of the patient perspective and to lower both economic and quality of life costs for patients and their families. To do so, ICER should incorporate the patient perspective as part of their base-case economic analyses; use appropriate real-world data sets for their analyses to reflect the actual patient community; meaningfully present alternative assumptions and sensitivity analyses; and work to incorporate and grow the data on caregiver impact and quality of life
AAFA Signs Letter Urging Clean Energy Deployment Incentives Through the Tax Code – October 2, 2019
AAFA and other health and medical organizations sent a letter to the House Committee on Ways and Means and the Senate Committee on Finance urging the committees to incentivize clean energy deployment through the tax code. Investments in clean energy are critical to combatting the harmful health effects of air pollution and climate change. Clean energy is better for our health and better for the climate. These incentives will lower pollution that threatens our health and exacerbates climate change, while improving health sector climate resilience.
AAFA Sends Support Letter for S.1276/H.1850 – September 18, 2019
AAFA sent a letter of support of S.1276/H.1850 to members of the Joint Committee on Public Health. S.1276/H.1850 is an act ensuring safe patient access to emergency care. Access to adequate emergency care is especially critical in Massachusetts where the asthma prevalence exceeds the national average. Most asthma-related deaths are preventable with proper management, housing improvements, better air quality, and, importantly, safe patient access to emergency care. AAFA therefore encourages the passage of S.1276/H.1850 to protect the lives of all Massachusetts residents living with asthma.
AAFA Signs Letter Supporting 100% Clean Energy Economy by 2050 – September 17, 2019
AAFA and eight other health and medical organizations sent a letter to representatives supporting the goal of a 100% clean energy economy by 2050 to improve public health, particularly in communities that are disproportionately vulnerable to air pollution and climate change impacts; and to prepare communities for climate impacts and risks. To fully protect public health, the nation must dramatically reduce greenhouse gas emissions while cleaning up other harmful emissions from polluting sources at the same time. The organizations urge the Representatives to continue prioritizing public health legislation is developed.
AAFA Signs Letter Urging Penicillin Skin Testing Product Review – August 15, 2019
AAFA and other public health and medical organizations emphasize to the Food and Drug Administration (FDA) that penicillin skin testing is essential for eliminating the increased morbidity and costs associated with a false label of penicillin allergy. A hindrance to penicillin testing is the lack of a commercial product containing the necessary reagents. The letter strongly urges the FDA to rapidly move forward with the review and potential approval process of a commercial product containing the essential penicillin antigens. This will enable the safest and most accurate identification of patients with true penicillin allergy.
AAFA Releases Statement on ICER Review of New Peanut Allergy Treatments – July 11, 2019
AAFA’s statement addresses concerns regarding the Final Evidence Report assessing the clinical effectiveness and value of treatments for peanut allergy released by the Institute for Clinical and Economic Review (ICER) on July 10, 2019. ICER’s report may cause concern for the allergy community that the findings will restrict access to new treatments for peanut allergy. ICER’s evaluation does not impact an approval nor denial from the Food and Drug Administration (FDA). AAFA agrees with ICER that we need more long-term data to focus on outcomes important to patients. AAFA advocates for considering quality of life for caregivers when evaluating childhood food allergy burden and outcomes.
AAFA Sends Comment Letter About Alcohol Labeling –June 26, 2019
AAFA sent a comment letter to the Alcohol and Tobacco Tax and Trade Bureau (TTB) on the proposed rule, “Modernization of the Labeling and Advertising Regulations for Wine, Distilled Spirits, and Malt Beverages.” AAFA supports transparent labeling about alcohol ingredients and urges the TTB to move toward mandatory allergen labeling on alcoholic beverages. Wines, distilled spirits and beers can contain undisclosed allergens, either used as processing agents or as ingredients. Research shows consumption of sediment particles containing these fining agents can cause allergic reactions.
AAFA Signs Letter Urging Joining of the Allergy and Asthma Caucus –June 24, 2019
AAFA, as part of the Childhood Asthma Leadership Coalition (CALC), signs letter urging Representatives to join the bipartisan Congressional Allergy and Asthma Caucus. The Caucus is a group of House Members dedicated to increasing awareness of the health and economic concerns associated with asthma and severe allergies, as well as advancing research to improve the lives of adults and children living with these conditions. CALC hopes that Representatives will consider promoting policies to address the needs of children with asthma.
AAFA Letter on ICER’s Review of Treatments for Peanut Allergy –June 14, 2019
The Institute for Clinical and Economic Review (ICER) and its California Technology Assessment Forum (CTAF) met on June 11, 2019 to assess the clinical effectiveness and value of treatments for peanut allergy. The review examined two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT). ICER invited AAFA to share recent research results that describe the burden of food allergies on patients and caregivers. AAFA wants to reassure people living with peanut allergy that FDA approval is still possible for these new treatments. AAFA looks forward to continued exploration of innovative ways to treat food allergies.
AAFA Signs Letter Expressing Concerns About H.R. 2009 – June 13, 2019
AAFA signs letter with other patient and consumer organizations expressing concern about H.R. 2009, the Removing Barriers to Allergy Diagnostic Testing Act of 2019. The letter states concern that if H.R. 2009 is enacted, it will lead to the indiscriminate use of allergy blood testing as a screening test and rather than its appropriate use as a confirmatory test. This will result in the misdiagnosis and mislabeling of people with food and/or inhalant allergies, which would be harmful to patients, result in unnecessary care and lifestyle restrictions and increase healthcare spending on unnecessary treatments. It is paramount that all allergy test results whether skin or blood must be confirmatory and interpreted in the context of the patient’s medical history.
AAFA Applauds DOT Warning About Denial of Preboarding to Family With Food Allergies – June 7, 2019
AAFA applauds the warning the U.S. Department of Transportation (USDOT) issued to American Airlines in response to American Airline’s denial of the right to pre-board a family of a child with food allergies. However, AAFA calls on the USDOT and Congress to take even stronger actions to protect the rights of airline passengers with allergies and all disabilities.
AAFA Signs Letter Urging Support For NIEHS/EPA Children’s Centers Funding – May 24, 2019
AAFA and other organizations sent letters to the Senate and House asking to signal strong support for joint funding for the NIEHS/EPA Children’s Environmental Health and Disease Prevention Research Centers (“Children’s Centers” or “Centers”). The grants that currently fund these 13 centers are due to expire in July and no announcement has been made to indicate renewed funding. The letter asks for support for the research necessary to understand how today’s environments impact children’s health and ability to learn.
AAFA Sends Letters Supporting Elijah’s Law – May 14, 2019
AAFA sent letters supporting Elijah’s Law to Senator Brian Benjamin (S218-A) and Assemblymember Al Taylor (A6971-A). New York State’s requirements for schools to have anaphylactic policies only apply to K-12 settings. Elijah’s law would apply important allergy requirements to all child day care providers. Providers would have to take concrete steps to manage food allergies for the children in their care, including developing emergency protocols, communication plans for discussing food allergies with children, and plans for preventing exposure. These requirements are evidence-based and will reduce reactions and risk for young children across the state.
AAFA Signs Letters Supporting Reauthorization of PCORI – May 13, 2019
AAFA and other organizations sent letters to the Senate and House expressing strong support for the reauthorization of the Patient-Centered Outcomes Research Institute (PCORI). In creating PCORI, Congress committed to build the evidence base for improved health decisions, seeking to empower patients and drive innovation and value in health care. Reauthorization is an opportunity for Congress to ensure that PCORI continues to uphold this commitment and serve the needs of an evolving health care system.
AAFA Signs Letter Urging Support of the Climate Action Now Act – April 29, 2019
AAFA and other public health and medical organizations urge Representatives to support H.R. 9, the Climate Action Now Act. The bill would help ensure that the United States adheres to the science-based targets in the Paris Agreement and develops a plan to meet them, both essential steps to protecting public health from the impacts of climate change. The nation urgently needs to implement strong, science-based measures to reduce the emissions that cause climate change. The U.S. must also invest in health mitigation strategies to help communities address the varied health impacts they are already facing.
AAFA Signs 2019 Declaration on Climate Change and Health – April 29, 2019
AAFA and other public health, patient advocacy, nursing and medical organizations declare climate change a health emergency and call for immediate action to protect the public’s health from the current and future impacts of climate change in the 2019 Declaration on Climate Change and Health. These organizations call on President Trump, EPA Administrator Andrew Wheeler, and members of Congress to heed the clear scientific evidence and take steps now to reduce pollution that drives climate change and harms health.
AFA Signs House Letter Applauding H.R. 1922 for OTC Medications – April 23, 2019
AAFA, as part of the Health Choices Coalition, signs letter sent to the House of Representatives applauding efforts via H.R. 1922 to restore over-the-counter (“OTC”) medications to full tax-preferred status, eliminating the need to first obtain a prescription. H.R. 1922 will create efficiencies and improve access to care within the U.S. healthcare system. The Coalition thanks the House for the efforts to restore consumers’ ability to pay for OTC medicines with tax preferred account funds without the need for a prescription and for broadening support for this legislation by crafting a bipartisan bill that extends HSA/FSA eligibility to feminine hygiene products.
AAFA Signs Senate Letter Applauding S. 1089 for OTC Medications – April 23, 2019
AAFA, as part of the Health Choices Coalition, signs letter sent to the Senate applauding efforts via S. 1089 to restore over-the-counter (“OTC”) medications to full tax-preferred status, eliminating the need to first obtain a prescription. S. 1089 will create efficiencies and improve access to care within the U.S. healthcare system. The Coalition thanks the House for the efforts to restore consumers’ ability to pay for OTC medicines with tax preferred account funds without the need for a prescription.
AAFA Sends Letter Urging Connecticut Atopic Dermatitis Legislation – April 5, 2019
AAFA sends letter on behalf of those suffering from atopic dermatitis (AD), also known as eczema, urging the Connecticut state legislature to pass legislation ensuring that any step therapy requirements enacted in Medicaid protect patients from medically harmful policies. Step therapy, without proper consumer and patient protections, have the potential to delay and restrict access to medically necessary and effective drugs and treatments. AAFA requests the implementation of policies to ensure that any measure incorporating step therapy for AD into Medicaid include patient protections.
AAFA Signs Letter Urging Prioritization of Food Allergy Research in FY2020 Appropriations – April 4, 2019
AAFA and 6 other organizations send letter to the Senate urging prioritization of food allergy research across the federal government in fiscal year 2020 (FY20) appropriations. The letter includes requests surrounding the Labor, Health and Human Services and Education, and Related Agencies (LHHS) and Defense. Continued investment in food allergy research through the Consortium on Food Allergy Research (CoFAR) and the National Institute of Allergy and Infectious Diseases (NIAID) has the potential to make serious strides towards understanding the causes of, and developing treatments for, this widespread and under-researched condition.
AAFA Signs Letter Urging Funding for CDC Climate and Health Program – March 22, 2019
AAFA and other public and environmental health organizations urge an increase in funding for the Centers for Disease Control and Prevention’s (CDC) Climate and Health Program to $15 million. Americans today experience negative health impacts due to climate change. Communities and states must have the resources necessary to understand specific current and anticipated health impacts of climate change and take steps to protect the public’s health. Further investment in the Climate and Health Program will help communities across the country better prepare and protect their residents.
AAFA Signs Letter Urging EPA to Retain Current Carbon Pollution Limits – March 18, 2019
AAFA and 10 other organizations urge the U.S. Environmental Production Agency (EPA) to retain the current limits, adopted in 2015, on carbon pollution for New, Modified and Reconstructed Stationary Sources. The nation experiences the damage from climate change today, and forecasts predict more devastation to come. EPA should be taking aggressive steps to address those challenges and greatly reduce the emissions of greenhouse gases and other harmful pollutants. A new EPA proposed rule would roll back and weaken existing policy, with no benefits to public health and with the potential to add millions of tons of the longest-lasting greenhouse gas to the problem.
AAFA Signs Letter Supporting Senate Bill 207 and Appropriation Request – March 11, 2019
AAFA and 26 other organizations support Senate Bill 207 and its associated $14.8 million budget appropriation request, which would include asthma preventive services as a covered benefit under the Medi-Cal program. SB 207 and the budget appropriation request will increase access for Medi-Cal beneficiaries to asthma education and home environmental asthma trigger assessments. Asthma is a significant public health problem and driver of health care costs. Increasing access to asthma education and home environmental asthma trigger assessments will help fulfill California’s Quadruple Aim of strengthening the quality of care, improving health outcomes, reducing health care costs and advancing health equity.
AAFA Signs Letter Requesting Funding for CDC’s NACP for FY 2020 – March 11, 2019
AAFA and 14 other organizations urge support from Senators/Representatives for an increase in funding for Fiscal Year 2020 for the Centers for Disease Control and Prevention’s (CDC) National Asthma Control Program (NACP). Specifically, support for a $5 million increase, bringing funding to $34.0 million for FY 2020, which would increase the number of states the program can fund to combat the human and economic burden caused by asthma. Asthma is a complex, multifactorial disease that requires a comprehensive approach and the NACP is making a difference in improving disease outcomes.
AAFA Signs Letter Urging Funding for CDC’s Program in FY 2020 – March 4, 2019
AAFA signs letter urging Congress to provide at least $7.8 billion for the Centers for Disease Control and Prevention’s (CDC) programs in the FY 2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. Congress should prioritize funding for all activities and programs supported by CDC which are essential to protect the health of the American people. The letter urges Congress’ continued support of the Prevention and Public Health Fund which currently makes up more than 10 percent of CDC’s budget and provides funding for critical public health and prevention activities.
AAFA Signs Letter Supporting Reintroduction of Climate Legislation – March 4, 2019
AAFA and other public health and medical organization thank Senator Edward J. Markey and Representative Matt Cartwright for their ongoing leadership to address the health impacts of climate change through your reintroduction of the Climate Change Health Protection and Promotion Act. Their legislation would help the public health and medical communities address the challenges of climate change and by prioritizing the public health response to climate change, it would bolster the capacity of our public health system and help to avoid many preventable illnesses and deaths.
AAFA Signs Letter Urging Funding for CDC NCEH in FY 2020 – February 26, 2019
AAFA and other public and environmental health organizations express support for increased funding for the Center for Disease Control and Prevention’s (CDC) National Center for Environmental Health (NCEH) in the FY 2020 Labor, Health and Human Services, Education, and Related Agencies Appropriations bill. The organizations urge Congress to provide at least $230 million to NCEH to ensure all its programs are adequately funded. Adequate investments today and into the future in core environmental health activities can be a critical down payment on health, productivity and happiness of countless Americans.
AAFA Applauds Senators Grassley and Wyden for Drug Pricing-Hearings – January 31, 2019
An estimated 16.2 million Americans are at risk for anaphylaxis – a severe allergic reaction. These people need access to affordable epinephrine auto-injectors. AAFA applauds Senators Chuck Grassley and Ron Wyden for holding hearings on drug pricing in America. This series of hearings demonstrates the senators’ commitment to exploring the problem of overpriced medications in America. AAFA particularly thanks Senator Grassley for highlighting the cost of epinephrine auto-injectors in his statement.
AAFA Signs Letter Urging CVS to Keep Primatene Mist HFA Behind the Counter – January 25, 2019
AAFA and 11 other patient and medical organizations urge Troyen Brennan, Chief Medical Officer at CVS Health, to consider keeping Primatene Mist HFA “behind the counter” to help reduce inappropriate use of this medication and to protect patients from adverse events. While the Food and Drug Administration (FDA) does not have the authority to require that OTC drugs be held behind the counter, pharmacies do have discretion to hold these products behind the counter in the interests of patient health and safety. The organizations urge placing inhaled epinephrine behind the counter to help best serve the needs of customers who have asthma.
AAFA Signs Letter Supporting ‘The American Lung Association Lung Health Cohort’ – January 18, 2019
AAFA and 8 other leading lung health and medical organizations write in support of a new epidemiologic cohort study, entitled “The American Lung Association Lung Health Cohort” (U01 HL146408‐01), submitted by a team of accomplished researchers in partnership with the American Lung Association’s Airways Clinical Research Centers (ACRC). These organizations believe that this study, which seeks to define and promote lung health, will develop targets to intercept and prevent chronic lung disease, and will also engage the broader scientific community in a population‐based effort to understand all forms of respiratory disease.
AAFA Signs Comment Letter on Proposed Healthy People 2030 Objectives – January 17, 2019
AAFA, as part of the Childhood Asthma Leadership Coalition (CALC), is concerned that the proposed objectives in Healthy People 2030 related to asthma are insufficient to capture the magnitude of the public health burden of asthma, or the impact of approaches to address it. The proposed objectives include seven objectives related to asthma, fifteen fewer than were included in Healthy People 2020. CALC supports the inclusion of the objectives proposed but urges HHS to restore a number of others to the final list of Healthy People 2030 objectives.
AAFA Letter to Weatherford, Texas, Independent School District on Treatment of Severe Allergic Reactions – January 16, 2019
AAFA sent letters to the superintendent, president and nurse coordinator of the Weatherford Independent School District to express concerns regarding their recent decision that personnel will administer Benadryl, rather than epinephrine, to some students displaying symptoms of anaphylaxis. AAFA is deeply concerned that this protocol – which is directly contradicted by medical evidence – could unnecessarily place many children in the Weatherford Independent School District in potentially deadly situations. AAFA urges the Weatherford Independent School District to reverse the new policy and implement appropriate, epinephrine-based protocols for addressing anaphylaxis.
AAFA Signs Letter Supporting Regulations to Label for Sesame – December 21, 2018
AAFA, along with other patient advocacy groups representing people with food allergies, sent a letter to the U.S. Food and Drug Administration (FDA) to express strong support of requiring allergen labeling and appropriate manufacturing practices for sesame. Sesame has become “the ninth allergen” and reactions to it can be severe.
AAFA Signs Letter Opposing Proposed Changes of the NSPS – December 17, 2018
AAFA and several other health and medical organizations sign letter expressing opposition to the changes proposed by the U.S. Environmental Protection Agency (EPA) to the Emission Standards for New, Reconstructed, and Modified Sources within the Oil and Natural Gas Sector, also referred to as the New Source Performance Standards (NSPS, or “the Rule”). The proposed rule changes will inflict significant harm on public health. Methane leaks accelerate climate change and thus increase health threats worldwide. Leaks of VOCs endanger the health of people living near oil and gas infrastructure. This would have the effect of increasing the health threats facing millions of Americans, as well as people around the world.
AAFA Sign On Letter on Draft of the Integrated Science Assessment for Particulate Matter – December 11, 2018
AAFA joined other patient advocacy groups to send a letter to the U.S. Environmental Protection Agency Draft Integrated Science Assessment for Particulate Matter (ISA). These organizations consider the review of the National Ambient Air Quality Standards (NAAQS) for particulate matter (PM) to be a top priority concern for the protection of public health, a position reinforced by the escalating evidence of its widespread harm.
AAFA Signs Onto Letter to Department of Homeland Security's Definition of “Public Charge” – December 10, 2018
AAFA joined other members of the Childhood Asthma Leadership Coalition on a letter to the Department of Homeland Security concerning their expansion of the definition of “public charge.” The expanded definition would consider the receipt or potential receipt of a broad range of public benefits as a negative factor against people seeking U.S. residency or citizenship. As leading advocates and experts in childhood asthma, public health, environmental health, poverty, housing, health care, and health care economics, CALC members are deeply concerned about the potential effects of this rule on children with asthma.
AAFA Signs Onto Letter Opposing the Medicare Part B International Pricing Index Model – December 10, 2018
AAFA joined the Part B Access for Seniors and Physicians Coalition express concern to Congress about a proposal by the Centers for Medicare & Medicaid Services (CMS) to implement an unprecedented, mandatory experiment affecting Medicare beneficiaries who take Part B-covered drugs. The proposed CMS International Pricing Index model would open the door for foreign-based price controls, preventing treatment based on evidence and best practices.
AAFA Signs Onto Letter Opposing EPA Proposal to Weaken Carbon Pollution Limits on New Power Plants – December 6, 2108
The U.S. Environmental Protection Agency (EPA) announced a proposal to dramatically weaken the Carbon Pollution Standards for New, Modified and Reconstructed Power Plants, which are protections against carbon pollution that have been in effect since 2015. In response, 15 health and medical groups sent a letter stating concern about the effects this can have on every American, especially American, but certain groups are more at risk – including children, older adults, pregnant women, low-income communities and communities of color.
AAFA Signs Onto Letter Asking Congress to Fully Fund the EPA in 2019 – November 29, 2108
AAFA joined a group of public health and medical organizations to urge Congress to fully fund the Environmental Protection Agency (EPA) and oppose all policy riders – including those that would block, weaken or delay critical clean air and public health protections for the Fiscal Year 2019.
AAFA Signs Onto Letter to FDA Asking for Sesame to Be Included as Major Allergen – November 27, 2108
The Congressional Asthma and Allergy Caucus sent this letter prepared by AAFA to FDA Commissioner Gottlieb urging the addition of sesame to the list of major food allergens.
AAFA Signs Onto Letter Asking EPA to Reconsider Limits on Air Toxics – November 14, 2108
AAFA joined other organizations to ask the U.S. Environmental Protection Agency (EPA) to abandon current plans to reconsider limits on mercury and other air toxics from power plants. The existing Mercury and Air Toxics Standards (MATS) are an EPA success story. The standards have achieved a 90% reduction in mercury emissions from power plants thanks to the controls that these facilities have installed in response to the rule. Rolling back these standards can be harmful to the health of millions of Americans.
AAFA Statement on FDA Approval of Primatene Mist for Mild Asthma – November 9, 2108
The FDA recently announced approval for the readmittance of Primatene Mist – an over-the-counter (OTC) epinephrine inhaler. In this letter, AAFA cautions patients to not stop their current asthma treatment nor start taking this OTC option without talking to their health care provider first.
AAFA Signs Onto Letter Opposing on the Affordable Clean Energy (ACE) Rule – October 31, 2018
Climate change poses grave threats to public health. To protect our communities and the public, the United States must significantly reduce carbon pollution from the largest stationary source, which is the nation’s fleet of existing power plants. As representatives of the medical and public health community, 12 organizations sent a letter on the U.S. Environmental Protection Agency’s (EPA’s) the replacement of the Clean Power Plan with the proposed Emission Guidelines for Existing Electric Utility Generating Units, commonly referred to as the Affordable Clean Energy (ACE) rule; the proposed revisions to emission guideline implementing regulations; and the proposed revisions to the New Source Review (NSR) Program.
AAFA Letter Applauding FDA Steps Toward Declaring Sesame as Major Allergen – October 30, 2018
Based on reports of adverse reactions from our community of over 55,000 food allergy patients, AAFA has advocated for the inclusion of sesame as a major allergen. The U.S. Food and Drug Administration (FDA) is now asking the public for more information about the prevalence of sesame allergy and sesame presence in food. AAFA applauds the FDA’s commitment to explore the classification of sesame as a major allergen.
AAFA Signs Onto Letter Opposing Safer Affordable Fuel-Efficient Vehicles Rule – October 26, 2018
AAFA and more than 90 health and medical organizations sent a letter to the U.S. Environmental Protection Agency (EPA) and the National Highway Traffic Safety Administration (NHTSA) opposing the proposed Safer Affordable Fuel-Efficient Vehicles Rule for Model Years 2021–2026 Passenger Cars and Light Trucks. This rule would rollback existing vehicle emission and efficiency standards and the Clean Air Act that protects citizens from harmful pollution.
AAFA Sends Letter to ICER About Draft Report on Biologic Therapies – October 22, 2018
AAFA sends comment letter to the Institute for Clinical and Economic Review (“ICER”) about their Draft Report “Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation” (September 24, 2018). AAFA appreciates that ICER is calling attention to the biologic therapy access and cost issues that impact the quality of life and sometimes longevity of life of Americans with asthma. However, AAFA believes that ICER understated or overlooked some important points in its analysis. ICER must make sure its analyses more accurately reflect comorbidities, incremental adverse events from chronic steroid use, and the intrinsic biologic variability of the inputs associated with asthma. Greater transparency and using real-world data in ICER’s modeling can make ICER’s work more helpful to patients who most need these therapies. Too little is known about the multi-year natural history of asthma, the real-world use of treatments (including adherence), and the cost and efficacy of the treatments.
AAFA Signs Letter Concerning Restoring Access to Medications and Modernizing Health Savings Account Act – October 22, 2018
AAFA has signed onto a letter from the Health Choices Coalition asking the Senate to pass H.R. 6199, the Restoring Access to Medication and Modernizing Health Savings Accounts Act of 2018. This would allow Americans to purchase over-the-counter medicines without a prescription using flexible spending arrangements (FSAs), health savings accounts (HSAs) and other tax-preferred accounts.
AAFA Signs Letter Opposing Policy Allowing Medicare Advantage Plans to Use Step Therapy for Drug Coverage – September 26, 2018
Along with several patient organizations, AAFA has signed a letter to the secretary of the Department of Health and Human Services opposing a proposed policy change that would allow Medicare Advantage plans to use step therapy for drug coverage. If this policy is passed, patients may have to take a drug that is not designed to treat their specific health circumstances, negatively impacting care.
AAFA Signs Letter Expressing Concern Over CMS Policy on Step Therapy for Part B Drugs – September 12, 2018
AAFA and several other patient organizations signed a letter to the leaders of Congress about concerns over a memo from the Centers for Medicare and Medicaid Services (CMS) that changes long-standing policy and allows Medicare Advantage (MA) plans to implement step therapy to manage Part B drugs in circumstances where applicable. Original Medicare policies do not require step therapy. CMS’ sudden and disruptive decision to allow the inappropriate use of step therapy policies is inconsistent with the requirement that MA plans provide coverage consistent with Original Medicare and threatens to restrict access and decrease therapy choices for patients. This could put patients’ health at risk and potentially creates long-term health care issues in the process.
AAFA Signs Letter Urging CVS Health to Stop Plans to Use ICER assessments for Drug Coverage September 12, 2018
AAFA and several other health and patient advocacy organizations have contacted CVS Health to urge them to abandon their recently-announced decision to consider denying coverage of drugs that fail to meet a cost-effectiveness threshold. The letter expresses deep concern that CVS Caremark will offer clients the option of formularies that rely on assessments from the Institute for Clinical and Economic Review (ICER) to deny coverage of drugs if they do not meet a subjective “quality-adjusted-life-year” (QALY)- based threshold. CVS’ reliance on a cost-effectiveness threshold is profoundly misguided and would prohibit affordable medications to populations who need it.
AAFA Signs Letter Urging Funding Increase for CDC NCEH in FY 2019 – September 6, 2018
AAFA and 36 other public and environmental health organizations sign letter to support increased funding for Centers for Disease Control and Prevention (CDC) National Center for Environmental Health (NCEH) in the FY 2019 Labor, HHS, Education appropriations bill. The letter urges that the proposed cuts in the House bill are restored and to provide at least $217 million to NCEH to ensure all of its programs are adequately funded. This funding will help ensure that NCEH can work to strengthen and expand its programs. Increasing our investments in environmental health prevention activities today will help reduce illness, disease, injury and even death.
AAFA Sends Letter Expressing Concerns About Epinephrine Shortage – August 24, 2018
AAFA’s President and Chief Executive Office, Kenneth Mendez, on behalf of the more than 15 million Americans living with life-threatening food allergies, expresses concerns to Secretary of the United States Department of Health and Human Services, Alex M. Azar II, about the recent shortages of epinephrine auto-injectors (EAI). This letter proposes solutions that can address the current “shortage” and make a difference for people with life-threatening allergies. Patient access to this life-saving drug must be restored, especially when there are options available. Now is the time for private insurance, pharmacy benefit companies, the federal government and pharmaceutical companies to work together and fast-track coverage for a readily available product. Such cooperation would save lives, solve a drug shortage issue and provide affordable treatment access to patients.
AAFA Signs Letter to Senate Opposing the ‘Relief from New Source Performance Standards Act’ – August 23, 2018
AAFA and nine other health and medical organizations urge the Senate to oppose S. 1857, the “Relief from New Source Performance Standards Act.” The bill delays lifesaving and long-overdue protections from air pollution from wood burning and would result in further harm to Americans’ health from toxic pollutants. These pollutants cause a range of adverse health effects including asthma attacks, heart attacks, lung cancer and premature deaths. The legislation would unnecessarily delay for three additional years the full implementation of standards for new wood-burning boilers, furnaces, and stoves to reduce emissions. The result would be years of premature deaths and health problems from wood smoke pollution that could have been prevented.
AAFA Signs Letter Opposing EPA’s Harmful Clean Power Plan ‘Replacement’ Proposal – August 22, 2018
AAFA and 9 other health and medical organizations oppose the Environmental Protection Agency's (EPA) release of the proposed Affordable Clean Energy (ACE) rule to replace the Clean Power Plan. As noted in the letter, the EPA's proposed replacement for the Clean Power Plan is not just inadequate, it is dangerous. The urgency of protecting public health from the impacts of climate change increases with each passing day—and so does the necessity of implementing and enforcing strong limits on carbon pollution from power plants as outlined in the Clean Power Plan. Our organizations urge EPA to reject the proposed rule and implement the Clean Power Plan. In addition to the immediate damage that this proposal would cause to human health, failing to address the pollution causing climate change will have lasting health consequences.
AAFA Signs Letter Opposing the EPA’s Proposed Rule “Strengthening Transparency in Regulatory Science” – August 16, 2018
AAFA, as part of the Childhood Asthma Leadership Coalition, opposes the Environmental Protection Agency’s (EPA) proposed rule, “Strengthening Transparency in Regulatory Science.” The rule provides that pivotal studies would need to rely on data that are available “in a manner sufficient for independent validation.” The Coalition is deeply concerned that in reality this provision would limit the use of research that could improve the lives of children with asthma, favoring deregulation over reasonable policymaking to protect and promote health. The letter urges EPA against moving forward with this proposed rule, and recommend that EPA solicit Science Advisory Board (SAB) review of any action regarding the standards around EPA research, to ensure that the EPA continues to promote the consideration of high-quality research that protects public health.
AAFA Signs Letter Strongly Opposing the Trump Administration’s Plan to Revoke Cleaner Cars Standards – August 2, 2018
AAFA and nine other health and medical organizations oppose a proposal from U.S. Environmental Protection Agency (EPA) and the National Highway Traffic Safety Administration (NHTSA) to weaken the 2021-2026 vehicle emissions and mileage requirements and withdraw the waiver that permits California to set more protective cleaner cars standards. This proposal from EPA and NHTSA would dismantle fair, achievable pollution limits with a track record of success, limits that will help protect Americans from the life-threatening health impacts of climate change. It would also preempt the ability of states to protect the health of their residents by curbing greenhouse gas emissions from vehicles. If these vehicle standards are weakened, the nation loses a crucial tool to fight climate change. Rolling back these standards is another step backward from the essential fight to avoid the worst impacts of climate change. From degraded air quality due to higher temperatures to increased risk from wildfires, climate change poses serious threats to all Americans, especially to the most vulnerable, including children, older adults and those living with chronic diseases.
AAFA Signs Comment Letter Regarding the HHS Blueprint to Lower Drug Prices and Reduce Out-Of-Pocket (OOP) Costs – July 16, 2018
AAFA and 52 other leading patient advocacy groups submitted a comment letter to the U.S. Department of Health and Human Services (HHS) regarding the ‘HHS Blueprint to Lower Drug Prices and Reduce Out-Of-Pocket (OOP) Costs’. The letter reflects that these organizations are ready to work with the HHS and other policymakers to implement policies, which ensure all patients in need have access to the prescription therapies their healthcare providers prescribe for them while at the same time incentivizing the development of innovative new medicines that can help patients get well, stay healthy, keep their condition from worsening and/or have a higher quality-of-life. These organizations wish to underscore that patient assistance programs provide a much-needed safety net for so many patients—in both commercial and publicly funded health plans—who simply cannot afford the ever-growing costs of their medications. Until all patients have affordable, unencumbered access to the therapies they need, patient assistance programs must continue their critically important work of giving much-needed financial support to patients who require costly medications to maintain or regain their health, well-being and quality-of-life.
AAFA Signs Comment Letter in Response to the President’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs – July 16, 2018
AAFA and 101 other patient groups, as a part of the I Am Essential coalition, submitted comments to the U.S. Department of Health and Human Services (HHS) in response to the ‘President's Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs’. The comment letter states the importance of access to medications to maintain healthy and full lives, prevent and cure diseases, and keep patients alive, particularly for those with chronic and serious health conditions. However, patients are bearing a greater share of healthcare costs at the pharmacy as a result of changes in plan benefit design by insurance companies that include high deductibles, high out-of-pocket maximums, along with rising copays and co-insurance. This letter suggests a number of proposals, including keeping prescription drugs outside the plan deductible or establishing a separate low drug deductible.
AAFA Submits Comment Letter Regarding ‘Traveling by Air with Service Animals’ – June 20, 2018
AAFA submitted a comment letter to the Docket Management Facility of the U.S. Department of Transportation (DOT) regarding the “Traveling by Air with Service Animals” Advance Notice of Proposed Rulemaking (ANPRM), docket number DOT-OST-2018-0068. AAFA recognizes the importance of accommodating those with disabilities who benefit from bringing a comfort animal on board a flight. However, a balanced policy must be achieved to also protect airline passengers who are at risk of severe allergic reactions to pet dander. An increase in the number of comfort animals allowed to board a flight unfortunately directly increases the risk to the health of those with animal allergies. The health and rights of passengers with asthma and allergies should not be subjugated to those with other disabilities who require comfort animals. AAFA applauds recent airline efforts to crackdown on growing abuse of the rules governing “comfort animal” on planes, and we welcome DOT’s initiative through this ANPRM to seek a balanced policy that accommodates all passengers with disabilities.
AAFA Submits Comment Letter to ICER Regarding Biologic Treatments for Asthma – June 5, 2018
AAFA submitted a comment letter to the Institute for Clinical and Economic Review (ICER) regarding its decision to ask patients with asthma about their experience with the disease to inform its newest report. As ICER notes in its Patient Guide to Open Input, assessing patient experience is imperative to creating a report that supports the policies and guidelines that are meaningful to patients with asthma. While AAFA supports biologics as a promising class of drugs to improve asthma outcomes, we urge ICER to consider cost structure and issues of affordability. AAFA is eager to continue to provide input to ICER to ensure that the needs and preferences of patients with asthma are appropriately taken into consideration within any larger push for policy development and/or change.
AAFA and Other Health Groups Urge the Senate to Oppose S. 263, the Ozone Standards Implementation Act of 2017 –April 23, 2018
AAFA and other health and medical organizations urge Senators to oppose S. 263, the “Ozone Standards Implementation Act of 2017”, as it delays lifesaving standards to reduce ozone pollution, or smog. It permanently weakens the Clean Air Act and future air pollution health standards for all criteria pollutants. The bill weakens implementation and enforcement of all lifesaving air pollution health standards, including those for carbon monoxide, lead, nitrogen dioxide, ozone, particulate matter, and sulfur dioxide. Clean air is fundamental for good health, and the Clean Air Act promises all Americans air that is safe to breathe. This bill is an attempt to undermine our nation’s proven clean air health protections.
AAFA Signs Comment Letter Opposing Short-Term, Limited-Duration Insurance Plan Proposed Rule – April 23, 2018
AAFA and 96 other patient groups submitted comments on the short-term, limited-duration insurance proposed rule (short-term plans) to the Department of Health and Human Services. These comments express serious concern regarding the reversal of previously established guardrails for enrollment in short-term plans and the impact it will have on the health of individuals, in particular those living with chronic and serious conditions. This rule, if finalized, will have a crippling effect on individuals’ healthcare and long-lasting implications on the stability of the health insurance market. Redefining short-term plans, as proposed, would take away comprehensive health benefits and patient protections, increase healthcare costs on individuals and the healthcare system, and put greater strain on the individual health insurance market.
AAFA Supports Letter Requesting Funding for CDC’s National Asthma Control Program – April 13, 2018
AAFA supports a ‘Dear Colleague’ letter from Senators Kirsten Gillibrand (D-NY) and Jeanne Shaheen (D-NH) to Chairman Roy Blunt and Ranking Member Patty Murray of the Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies. This letter was signed by 18 Senators and requests funding for a $30 million appropriation in fiscal year 2019 for the National Asthma Control Program (NACP) at the Centers for Disease Control and Prevention (CDC). The NACP tracks asthma prevalence, promotes asthma control and prevention, and builds capacity in state and community health program. This program trains educators and health professionals to diagnose, treat and manage asthma. These funds will help to reduce the burden of asthma and continue to keep our communities and children healthy.
AAFA Signs Letter Urging Funding for CDC Programs in FY 2019 – April 9, 2018
AAFA and 152 other members of the CDC Coalition and other supporting state and national organizations urge Congress to provide $8.445 billion for the Centers for Disease Control and Prevention’s programs in the FY 2019 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. We believe that Congress should prioritize funding for all of the activities and programs supported by CDC which are essential to protect the health of the American people. In addition to ensuring a strong public health infrastructure and protecting Americans from public health threats and emergencies, CDC programs are crucial to reducing health care costs and improving health.
AAFA Signs Letter for Funding Increase for CDC’s National Asthma Control Program for FY 2019 – March 8, 2018
AAFA and 14 other organizations urge support from Senators/Representatives for an increase in funding for Fiscal Year 2019 for the Centers for Disease Control and Prevention’s (CDC) National Asthma Control Program (NACP). Specifically, support for a $1 million increase, bringing funding to $30.0 million for FY 2019, which would ensure the program can continue to assist states with combatting the human and economic burden caused by asthma. Asthma remains a serious and costly health issue in our nation and the NACP is making a difference in improving disease outcomes.
AAFA Signs Comment Letter Opposing the Association Health Plans Proposed Rule – March 6, 2018
AAFA and 117 other patient and community organizations submitted comments on the Department of Labor’s proposed rule issued on January 5, 2018 that expands the scope and applicability of Association Health Plans (AHPs). The letter comments that the proposed changes would negatively impact access to quality, affordable care for consumers, disrupt the individual and small business marketplace, and further strain the limited resources of state regulators. AAFA and the other organizations are committed to supporting access and coverage for the healthcare needs of individuals living with chronic and serious conditions, and are concerned that the proposed rule, if finalized, would fail to provide the critical health coverage, quality health care and benefits necessary to meet the needs of patients.
AAFA Signs Letter Opposing the Relief from New Source Performance Standards Act – March 5, 2018
AAFA and other health and medical organize sign on to letter opposing H.R. 453, or the “Relief from New Source Performance Standards Act.” The bill, which delays lifesaving and long-overdue protections from air pollution from wood burning and would result in further harm to Americans’ health from toxic pollutants, has been incorporated into Section 3 of H.R. 1917, the “BRICK Act.” Wood smoke from residential wood heaters is a significant source of air pollution that harms human health, especially for people with asthma and other lung diseases. The legislation would unnecessarily delay for three additional years the full implementation of standards for new wood-burning boilers, furnaces, and stoves to reduce emissions.
AAFA Signs Letter Surrounding Fiscal Year 2019 National Defense Authorization Act (NDAA) Language – February 27, 2018
AAFA and other health organizations sign on to letter urging House and Senate to consider specific language for the fiscal year 2019 National Defense Authorization Act (NDAA). These organizations encourage refraining from including any language that would have a detrimental impact on research at the Congressionally-Directed Medical Research Program (CDMRP) and other medical research conducted by the U.S. Department of Defense (DoD). The strong level of bipartisan Congressional support for the defense health research programs is a beacon of hope to the military families, retirees, veterans and civilians who must cope with these diseases and disorders.
AAFA Signs Comment Letter on the Advance Notice of Proposed Rulemaking for State Guidelines for Greenhouse Gas Emissions – February 26, 2018
AAFA and other health organizations sign on to comment letter on the Advance Notice of Proposed Rulemaking for State Guidelines for Greenhouse Gas Emissions from Existing Electric Utility Generating Units. This letter to Scott Pruitt urges the Environmental Protection Agency to return to the implementation of the Clean Power Plan to best reduce carbon dioxide and its threats to the health of Americans, and to not pursue any further actions to develop a weaker, flawed and potentially harmful alternative. The risk of climate change demands EPA act immediately to curb release of greenhouse gases to protect the health of Americans.
AAFA Releases Statement on Bronchial Thermoplasty – February 20, 2018
AAFA releases statement of support of bronchial thermoplasty (BT), which is a drug free treatment option for some people whose asthma symptoms are not improved by other medication. BT can help people to better control their severe asthma and result in a decrease in the number and severity of asthma attacks. AAFA urges health plans and insurance carriers cover the costs of this procedure for those whose severe asthma is not well managed by less invasive therapies and whose physicians deem it appropriate.
AAFA Signs On to Letter Opposing EPA’s Proposed Repeal of Emission Requirements for Gliders – January 5, 2018
AAFA and 11 other health and medical organizations urge EPA’s Administrator Scott Pruitt to retain and implement the current Phase 2 GHG Emissions and Fuel Efficiency Standards for Medium- and HeavyDuty Vehicles, and not to repeal the emissions requirements for glider vehicles, glider engines and glider kits. These standards will not only help to mitigate climate change and its associated health risks, but will also significantly reduce emissions of toxic and carcinogenic air pollutants, benefiting public health in communities across the country.
AAFA Signs On to Letter Urging An Immediate Five Year Extension of the Children’s Health Insurance Program (CHIP) – December 21, 2017
AAFA and over 1,000 other organizations urge leaders of the Senate and House of Representatives to immediately enact a five-year extension of the Children’s Health Insurance Program (CHIP). CHIP funding expired on September 30, 2017 and as federal funding to the states is running out, families across the country are receiving disenrollment notices and face an uncertain future about their children’s health care. CHIP has been an essential source of children’s coverage, ensuring access to high-quality, affordable, pediatric-appropriate health care for children in working families whose parents earn too much to qualify for Medicaid but too little to purchase private health insurance on their own. CHIP has played a critical role in reducing the number of uninsured children by more than 68 percent, from nearly 15 percent in 1997 to less than five percent in 2015, while improving health outcomes and access to care for children and pregnant women.
AAFA Signs On to Letter Urging House and Senate to Provide Funding For CDC Programs for FY2018 – December 4, 2017
AAFA and other organizations urge the House and Senate to provide at least $7.8 billion for the Centers for Disease Control and Prevention’s programs as a final FY 2017 Labor, Health and Human Services, Education and Related Agencies Appropriations bill or other final FY 2018 funding legislation is being developed. These organizations urge the rejection of inclusion of any controversial policy riders that would threaten public health, and believe that Congress should prioritize funding for all of the activities and programs supported by CDC. CDC programs are essential to protect the health of the American people, reducing health care costs and improving health.
Defense Health Research Protected in Final FY18 National Defense Authorization Act – November 9, 2017
Thanks to the nationwide grassroots advocacy led by the Defense Health Research Consortium (DHRC) and its allied organizations, including AAFA, the final House-Senate conference report to the fiscal year 2018 National Defense Authorization Act will not include four provisions restricting medical research at the Department of Defense (DoD).
AAFA Signs On to Letter In Response to EPA Announcement to Revoke the Clean Power Plan – October 10, 2017
AAFA and 18 other health organizations oppose the EPA announcement to revoke the Clean Power Plan, stating that this is inconsistent with EPA's core mission of protecting public health and the environment. Per the letter, revoking this lifesaving plan denies Americans these health protections and removes crucial tools to reduce pollution that causes climate change.
AAFA Signs On to Letter Urging Senators to Support the Durbin-Blunt Amendment – July 27, 2017
AAFA and other organizations urge Senators John McCain and Jack Reed to support the bipartisan Durbin-Blunt amendment to nullify several provisions related to medical research included in S. 1519, the fiscal year 2018 National Defense Authorization Act. As reported by the Senate Armed Services Committee, S. 1519 would have the effect of severely restricting, and in some cases terminating, critical medical research programs funded by the Department of Defense (DoD).
AAFA Re-Signs On to Letter Opposing the Ozone Standards Implementation Act of 2017 And Its New Amendment –July 17, 2017
AAFA and other health organizations urge Congress to oppose the Ozone Standards Implementation Act, which would delay long-overdue updated ozone standards and permanently weaken the Clean Air Act and the health protections it provides for Americans, particularly seniors, children and people living with chronic disease, against dangerous air pollutants. A new amendment added to the letter that was adopted in committee would eliminate key enforcement provisions under the Clean Air Act.
AAFA Signs On to Letter Opposing the Ozone Standards Implementation Act of 2017 – June 27, 2017
AAFA and other health organizations urge Congress oppose the Ozone Standards Implementation Act, which would delay long-overdue updated ozone standards and permanently weaken the Clean Air Act and the health protections it provides for Americans, particularly seniors, children and people living with chronic disease, against dangerous air pollutants.
AAFA and Other Organizations Issue a Declaration on Climate Change and Health – June 19, 2017
AAFA and other public health, patient advocacy, nursing and medical organizations reiterate their longstanding commitment to addressing climate change as a public health issue. The Declaration on Climate Change and Health articulates their consensus on the health impacts of climate change and the need for action to protect the public’s health.
AAFA Supports the Formation of an FDA Office of Patient Affairs – June 12, 2017
AAFA joins other health organization in support of the proposed formation of an FDA Office of Patient Affairs to coordinate opportunities for patient involvement in medical product development and regulation at FDA, as well as better assist patients and patient organizations desiring to get more involved. AAFA joins others in also suggesting additional ways to improve this proposal, particularly by harnessing patient engagement capabilities already present in the Office of the Commissioner, and by ensuring such an office does not act as a barrier to existing relationships.
AAFA Supports Funding of Defense Health Research Programs – June 8, 2016
AAFA and other health organizations request the continued support of the Senate and House for the critical and highly successful defense health research programs funded through the Congressionally Directed Medical Research Programs (CDMRP) at the Department of Defense (DoD), as they begin work on the Fiscal Year 2018 Defense Appropriations bill.
AAFA and Other Health Groups Oppose the Ozone Standards Implementation Act of 2017 in Letter to Senate – May 23, 2017
AAFA and other health organizations urge Senators to oppose the Ozone Standards Implementation Act, which would delay long-overdue updated ozone standards and permanently weaken the Clean Air Act and the health protections it provides for Americans, particularly seniors, children, and people living with chronic disease, against dangerous air pollutants.
AAFA Urges Congress to Oppose the EPA Science Advisory Board Reform Act and the Honest and Open EPA Science Treatment Act – March 27, 2017
AAFA joins other health organizations to oppose these two bills which would restrict the input of scientific experts in the review of complex issues and add industry influence into the EPA’s decision-making process. The EPA Science Advisory Board Reform Act would limit the voice of scientists, and the HONEST Act would limit the kinds of scientific data EPA can use as it develops policy.
AAFA Signs On to Letter Opposing the Ozone Standards Implementation Act of 2017 – March 22, 2017
AAFA and other health organizations urge Congress oppose the Ozone Standards Implementation Act, which would delay long-overdue updated ozone standards and permanently weaken the Clean Air Act and the health protections it provides for Americans, particularly seniors, children and people living with chronic disease, against dangerous air pollutants.
AAFA Signs On to Letter to Department of Health and Human Services Discussing Market Stabilization – March 8, 2017
AAFA and other organizations write to Secretary Tom Price of the Department of Health and Human Services to express thoughts and concerns over the recent proposed rule on market stabilization and the potential impact on patients and providers.
AAFA Joins Other Organizations to Urge Congress to Oppose Harmful Regulation Bills – February 28, 2017
AAFA and other health organizations urge Congress to Oppose H.R.998, H.R.1004, and H.R. 1009. Each of these bills would make effectively make it harder to protect the public health of Americans.
AAFA Joins CSPI in Support of Adding Sesame to Labeling on Food Packages – February 27, 2017
AAFA joins the Center for Science in the Public Interest to urge the Food and Drug Administration to further consider adding sesame to the list of ingredients that must be disclosed on food labels.
Organizations Urge President Trump to be Mindful of Role of Federal Public Health and Biomedical Research Workforce – February 27, 2017
AAFA and other organizations urge President Trump to continue to recognize the essential role of the federal workforce and the many public health and biomedical research jobs are critical to protecting public safety and national security.
AAFA Supports Call for Children’s Initiative on School Infrastructure and Environmental Health – February 22, 2017
AAFA joined other organizations to support a federal children’s initiative which will recognize childrens unique vulnerability to environmental health hazards, reduce environmental risks, generate benefits for children, save taxpayer money and provide local jobs to many communities around the country.
AAFA Joins Other Patient Groups Urging Secretary Price to Maintain Patient Protections – February 14, 2017
AAFA signed a letter urging new U.S. Department of Health and Human Services Secretary Tom Price to maintain and enforce the ACA’s patient protections as he reviews the law and its implementing regulations.
AAFA Joins Other Organizations to Urge Congress to Approve the 2017 Defense Appropriations Act – February 8, 2017
AAFA signed onto to letter urging Congress to complete the final negotiations on the 2017 Defense Appropriations Act and to move the bill through the House and Senate toward enactment. Any further delay and failure to enact the final bill will have major negative health implications for millions of Americans, especially veterans.
AAFA Signs On to Letter to the Senate Encouraging Congress to Retain Current Patient Protections – February 6, 2017
AAFA Signs On to Letter to the House of Representatives to Encourage Congress to Retain Current Patient Protections – February 6, 2017
AAFA joins other health organizations to encourage the Senate and House of Representatives to retain protections for patients as they move forward with efforts to repeal, modify or replace the Affordable Care Act. The patient protections that have been in place since 2014 include prohibiting pre-existing condition exclusions, restricting premium ratings, banning annual and lifetime benefit limits, and prohibiting coverage rescissions.
AAFA Signs On to Letter Opposing Blocks to Air Pollution Limits – February 1, 2017
AAFA joined other medical and public health organizations urging Congress to oppose any Congressional Review Act resolution of disapproval that would block air pollution limits that address the leakage of methane.
AAFA Supports Light Duty Vehicle Greenhouse Gas Emissions Standards – January 10, 2017
AAFA supports the proposed determination on the appropriates of light duty vehicle greenhouse gas emissions standards under the midterm evaluation. These standards remain appropriate under the Clean Air Act and support strengthening these standards going forward to further reduce greenhouse gas emissions.
AAFA Joins Other Organizations to Provide View on the Importance of the Medicaid Program – January 6, 2017
AAFA and other healthcare organizations urge Congress to understand the importance of the Medicaid program and how it works to improve the health of underserved communities.
AAFA Joins Health Organizations to Oppose the Regulatory Accountability Act of 2017, H.R.5. – December 29, 2016
AAFA joined other public health and medical organizations urging Congress to oppose H.R.5, which would undermine the federal government's ability to set lifesaving public health protections by requiring federal standards to be based on industry cost estimates and not what best protects the public.
AAFA Signs on to Letter Opposing Harmful Policy Riders – December 2, 2016
AAFA signs on to letter urging Congress to oppose all harmful policy riders that would block, weaken or delay critical clean air and public health protections.
AAFA Signs Letter Urging Congress to Approve Funding for Defense Health Research Programs – November 18, 2016
AAFA and 65 other health organizations signed a letter urging Congress to complete the 2017 Defense Appropriations Act which includes strong funding for medical research. Millions of American veterans, military retirees, military families, and civilians benefit from the ongoing research funded by the Defense Health Research Programs at the Department of Defense.
AAFA Comments on New Model for School Health Services in DC – October 25, 2016
AAFA provided comments expressing concern over the new model for school health services that will be implemented in D.C. public schools and public charter schools starting in January 2017.
FDA Guidance on Insanitary Condition at Compounding Facilities – October 24, 2016
AAFA submitted comments in opposition of the draft guidance by the Food and Drug Administration (FDA) titled, Insanitary Conditions at Compounding Facilities: Guidance for Industry. AAFA is concerned that the proposed guidance would severely limit patients’ access to immunotherapy and would create barriers to allergy treatment.
Greenhouse Gas Emission Standards for Light Duty Vehicles – October 3, 2016
AAFA signed on to a comment letter discussing the impact of federal standards for greenhouse gas emissions for light duty vehicles on human health and climate change.
The Health Harms of Biomass – September 14, 2016
AAFA signed a letter urging Congress to oppose policies which would increase the use of biomass in the production of electricity.
AAFA Joins PIPC in Response to ICER – September 14, 2016
AAFA signed a letter from the Partnership to Improved Patient Care in response to the call for input from ICER.
AAFA Encourages ICER to Incorporate the Patient Perspective – September 13, 2016
The Institute for Clinical and Economic Review (ICER) is an independent non-profit organization that evaluates medical evidence and helps stakeholders interpret and apply evidence to improve patient outcomes and control costs. AAFA submitted comments emphasizing the need to include patients' perspectives in response to an ICER call for comments on how to improve their value framework development process.?
AAFA Letter About Rising Costs of Epinephrine Auto-Injectors – August 24, 2016
AAFA’s CEO addresses issues of access and affordability of life-saving epinephrine auto-injectors.
Proposed Revisions to the Regional Haze Rule – August 10, 2016
AAFA and other organizations signed a letter to the EPA in support of proposed revisions that will strengthen the Regional Haze Rule. We also urged the EPA to reconsider updates that would weaken reporting requirements and delay emission reductions.
Kentucky Medicaid Allergy Testing Coverage – July 21, 2016
AAFA commented on a proposed change in Kentucky that would eliminate Medicaid coverage for allergy testing.
Nitrogen Oxide Emissions – July 19, 2016
AAFA signed a letter urging the EPA to propose a new standard to cut emissions of nitrogen oxides from trucks.
Near-Road Monitoring – June 30, 2016
AAFA and other health organizations signed a letter to the EPA expressing concern about potential plans to reduce the near-road monitoring program, which monitors air pollution near roadways.
Medicare Part B Payments – June 28, 2016
AAFA and other patient organizations signed a letter to Congress listing patient concerns about proposed changes to Medicare Part B payments.
School-Based Medicaid Programs – June 27, 2016
We signed a letter to CMS urging improvements to school-based Medicaid programs and better school health initiatives.
Allergy Immunotherapy and Compounding – June 6, 2016
AAFA’s President and CEO spoke at an FDA meeting about regulations that might impact patient access to allergy shot treatments.
National Defense Authorization Act – June 1, 2016
AAFA signed a letter in opposition to certain sections of the National Defense Authorization Act, which would prohibit funding for most medical research at the Department of Defense (DoD). This limit on medical research could harm the health and well-being of military families.
Letter To NBC: Jokes About Food Allergies Can Put People in Danger – May 12, 2016
AAFA sent a letter to NBC expressing concern over a Today Show segment that belittled the severity of food allergies.
Air Travel and Disabilities – May 10, 2016
AAFA commented to the Department of Transportation explaining why asthma and allergies should be taken into consideration as disabilities during airline travel.
Medicare Part B Payment Program – May 9, 2016
AAFA submitted separate comments to CMS about the proposal to change Medicare Part B payment in a way that could negatively impact patients with chronic or complex conditions.
Medicare Part B Payment Program – May 9, 2016
We signed a letter in opposition to a CMS proposal that would change Medicare Part B payment in a way that could negatively impact patients with chronic or complex condition
Allergy Protocols in Federal Facilities – April 22, 2016
AAFA sent a letter to Federal Occupational Health (FOH) in support of epinephrine stocking and improved allergy policies in federal facilities.
Children’s Health Programs – April 20, 2016
We signed a letter from the Coalition for Healthier Schools in support of funding for children’s health programs at the U.S. EPA.
National Center for Environmental Health Funding – April 20, 2016
We signed a letter in support of funding for the CDC’s National Center for Environmental Health.
National Asthma Control Program – April 4, 2016
AAFA signed a letter in support of funding for the CDC’s National Asthma Control Program.
Climate Change and Health – April 4, 2016
In recognition of National Public Health Week, AAFA and other health organizations signed an official Declaration on Climate Change and Health.
Medicare Advantage Cuts – March 31, 2016
AAFA and other health organization sent a letter to the Centers for Medicare and Medicaid Services to express concern about cuts to Medicare Advantage.
Medicare Payments – March 25, 2016
We joined with other health and medical organizations to sign a letter regarding Medicare Part D recommendations.
Agency for Healthcare Quality and Research Funding (House) – March 14, 2016
We signed a letter to Congress in support of funding for the Agency for Healthcare Quality and Research (AHRQ).
School-Based Asthma Management Programs Act – March 7, 2016
AAFA sent a letter of support to the sponsors of the School-Based Asthma Management Programs Act (HR 4662).
AAFA Comments on Allergen Immunotherapy at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting – March 7, 2016
AAFA’s former CEO, Dr. Cary Sennett, spoke at the AAAAI meeting about the importance of allergen shot treatments. Proposed changes to USP 797 pose a threat to patients by disrupting access to allergy immunotherapy.
Diversity in Clinical Trials – February 29, 2016
AAFA’s Senior Vice President of Policy, Advocacy, and Research, Meryl Bloomrosen, spoke at an FDA meeting about the importance of diversity in clinical trials and involving patients in research.
South Carolina’s Emergency Anaphylaxis Treatment Act – February 23, 2016
AAFA sent a letter in support of South Carolina’s Emergency Anaphylaxis Treatment Act, which would expand access to epinephrine in public places.
Clean Power Plan – February 12, 2016
Along with other health organizations, we signed a letter to the National Governors Association urging state governors to move forward with the EPA’s Clean Power Plan.
School Asthma Policies – February 1, 2016
We sent a letter to the Congressional Allergy and Asthma Caucus expressing concern about recent asthma emergencies in Texas schools.
Allergen Immunotherapy – January 29, 2016
We submitted comments regarding proposed regulations that could threaten the availability of immunotherapy treatments (allergy shots) in the United States.
Amtrak Pet Policy – January 29, 2016
AAFA sent a letter to Amtrak leadership expressing concern about a pilot program that would allow pets to travel on trains.
Amtrak Response to AAFA – February 9, 2016
Read Amtrak's response to AAFA's letter.
Food Labeling Modernization Act – January 27, 2016
AAFA sent a letter to the sponsors of the Food Labeling Modernization Act of 2015 to thank them for introducing the legislation.
FDA Allergenic Products Advisory Committee Spoken Comments – January 21, 2016
AAFA CEO Cary Sennett represented allergy patients’ perspective in testimony before the FDA’s Allergenic Products Advisory Committee.
FDA Allergenic Products Committee Presentation
Smoke-Free Housing – January 19, 2016
AAFA submitted comments to the Department of Housing and Urban Development (HUD) in support of HUD’s proposed ban on smoking in public housing units.
Every Student Succeeds Act – January 21, 2016
As part of the Working to Improve Student Health (WISH) coalition, AAFA signed a letter in support of the Every Student Succeeds Act (ESSA).
Nucala™ (Mepolizumab)Comments – January 12, 2016
We submitted comments to the Institute for Clinical and Economic Review (ICER) regarding Nucala (Mepolizumab) treatment for asthma.
Nucala™ Mepolizumab Cover Letter
Protection of Research Participants – January 6, 2016
AAFA sent comments to the Department of Health and Human Services about how to update and improve protections for patients participating in clinical research.
Health Homes Program – December 21, 2015
We signed a letter in support of including asthma as one of the chronic conditions addressed by California’s Department of Health Care Services’ Health Homes Program.
Assistant Secretary for Health at HHS – November 24, 2015
AAFA and other organizations signed a letter in support of Dr. Karen DeSalvo’s nomination for Assistant Secretary for Health at the Department of Health and Human Services.
FDA Patient Engagement Advisory Committee – November 20, 2015
AAFA submitted comments to the FDA expressing disappointment that the FDA was not planning to include a greater number of patient representatives on the Patient Engagement Advisory Committee.
EPA Carbon Limit Protection (Senate) – November 16, 2015
EPA Carbon Limit Protections (House of Representatives) – November 16, 2015
AAFA joined other health organizations in signing a letter to the Senate and the House of Representatives opposing two Congressional Review Acts (CRA) that would block the EPA’s Clean Power Plan and carbon limits for new power plants.
CDC Funding – November 16, 2015
AAFA signed a letter to Congress to support strong funding for the CDC in any Fiscal Year 2016 spending legislation.
AHRQ Funding (Senate) – October 22, 2015
AHRQ Funding (House of Representatives) – October 22, 2015
AAFA signed a letter to Congress to support funding for the Agency for Healthcare Research and Quality (AHRQ).
Medication Therapy Management (MTM) – October 16, 2015
AAFA signed a letter to Senators Isakson and Warner, co-chairs of the Senate Finance Committee Chronic Care Working Group, to support the Medication Therapy Management Empowerment Act of 2015 in their legislative efforts.
National Asthma Control Program – September 11, 2015
AAFA and other organizations supported funding for the CDC’s National Asthma Control Program in Fiscal Year 2016.
Institute of Medicine Food Allergy Study – August 30-September 1, 2015
AAFA commented to the Institute of Medicine regarding the study Food Allergies: Global Burden, Causes, Treatment, Prevention, and Public Policy.
Ozone Pollution Limit – August 11, 2015
We signed a letter to President Obama to show support of better ozone limits in the air.
The Elementary and Secondary Education Act – August 7, 2015
We signed a letter to Congress to support an asthma management provision in the Elementary and Secondary Education Act (ESEA).
Medication Therapy Management – August 6, 2015
We signed a letter asking the Centers for Medicare and Medicaid Services (CMS) to allow more at-risk elderly patients to participate in the Medicare Part D Medication Therapy Management (MTM) program.
Clean Air Protections – August 4, 2015
We joined other health and medical groups to stand against a bill that would affect how clean the air is. This includes the Clean Air Act and the Clean Power Plan.
The Clean Power Plan – August 3, 2015
We praised the President’s message of the EPA’s Clean Power Plan Final Rule.
A Declaration on Climate Change and Health – June 23, 2015
We joined other groups to restate the public health community’s promise to look at climate change as a health issue.
Secondary Preventive Services – June 19, 2015
We signed a letter of support to the Treasury Secretary Jack Lew about secondary preventive services. These keep a disease or illness from getting worse. They also help those with asthma manage it and prevent related problems.
Electronic Health Records – June 15, 2015
We sent comments to the CMS about possible changes to the Electronic Health Record Incentive Program.
Improving Care for Medicare-Aged Population – June 14, 2015
We sent comments to the Senate Chronic Care Working Group. We offered options for better care for Medicare patients.
Part D Beneficiary Appeals Fairness Act – June 1, 2015
AAFA signed a letter in support of the Part D Beneficiary Appeals Fairness Act. This enables seniors to appeal if their medication is put on a Medicare Part D Specialty Tier.
National Heart, Lung, and Blood Institute Strategic Vision – May 15, 2015
We sent comments to the National Heart, Lung, and Blood Institute (NHLBI) about research for the next 10 years.
The Family Asthma Act of 2015 – May 15, 2015
We support the Family Asthma Act of 2015. This act would make asthma research and public education better in the United States.
The School Asthma Management Plans Act – May 15, 2015
We support the School Asthma Management Plans Act. This would allow schools to improve how they manage asthma care.
NIH Innovation Fund – May 13, 2015
AAFA signed a letter to support funds for the National Institutes of Health (NIH) included in the 21st Century Cures Act draft bill.
The Climate Change Health Promotion and Protection Act – April 13, 2015
We signed a letter to Representative Lois Capps. We thanked her for bringing back the Climate Change Health Promotion and Protection Act. This act would help address the threat of climate change on health.
Ratepayer Protection Act – April 13, 2015
AAFA and other health groups signed a letter against to the Ratepayer Protection Act. This act would delay and block critical clean air protections.
Medication Costs and the Impact on Patients – April 9, 2015
AAFA’s former CEO, Dr. Cary Sennett, spoke at a congressional briefing about the impact rising medication costs will have on patients
Children’s Health Programs Funding – March 26, 2015
We signed a letter to support more money for federal programs that help schools reduce indoor air pollution. This would occur through the Environmental Protection Agency’s (EPA)’s office of Children’s Health Protection and the Office of Radiation and Indoor Air.
Agency for Healthcare Research and Quality Funding – March 20, 2015
We signed a letter against ending the Agency for Healthcare Research and Quality (AHRQ) in the House Labor HHS Subcommittee’s 2016 spending bill.
Ozone Standards – March 17, 2015
AAFA and other health groups sent comments to the U.S. Environmental Protection Agency (EPA) on the proposed National Ambient Air Quality Standards. This would limit the amount of harmful ozone in the air.
Dormant Therapies and 21st Century Cures – March 17, 2015
AAFA and other health groups signed a letter that the Dormant Therapies Act be included in the 21st Century Cures Act draft bill. This would help develop new cures for diseases. It would improve the quality of life for Americans with chronic diseases.
National Asthma Control Program – March 11, 2015
AAFA and other asthma organizations signed a letter to support more money for the National Asthma Control Program at the Centers for Disease Control and Prevention (CDC).